Convelo, Genentech to collaborate on remyelination drugs for MS

Convelo, Genentech to collaborate on remyelination drugs for MS

US biotech company Convelo Therapeutics has signed an exclusive worldwide collaboration with Roche subsidiary Genentech to fast track discovery and development of novel remyelination drugs for the treatment of multiple sclerosis (MS) and other neurological disorders. Convelo Therapeutics, which is headquartered in Cleveraland, Ohio, is engaged in discovering a new class of drugs that regenerate the […]

Genentech gets Kadcyla FDA approval for post-surgery treatment of HER2+ EBC

Genentech gets Kadcyla FDA approval for post-surgery treatment of HER2+ EBC

Kadcyla FDA approval : Roche subsidiary Genentech has secured approval from the US Food and Drug Administration (FDA) for its breast cancer drug Kadcyla (ado-trastuzumab emtansine) for post-surgery treatment of HER2-positive early breast cancer (EBC) in patients with residual invasive disease who were subjected to before surgery taxane and Herceptin (trastuzumab)-based treatment. The Kadcyla FDA […]

FDA approves Genentech’s lucentis for comprehensive diabetic retinopathy treatment

The US FDA has approved lucentis (ranibizumab injection) for diabetic retinopathy treatment. Read the Lucentis FDA approval story in our pharma news updates section at DailyHealthNeeds.com.

FDA approves Genentech’s lucentis for comprehensive diabetic retinopathy treatment

Genentech, a member of the Roche Group, has received approval from the U.S. Food and Drug Administration (FDA) for its lucentis (ranibizumab injection), making it the first medication approved in the U.S. for the treatment of all forms of diabetic retinopathy, whether accompanied by diabetic macular edema (DME) or not. Pioneering Treatment for Diabetic Retinopathy […]